PT-141 (Bremelanotide)
UK status now cites an MHRA Products database search (no UK authorisation found). An unsourced statement about the reason was removed.
Regulatory updateAOD-9604
A finding based on an unidentifiable early-phase source was removed, as was an unsourced toxicology statement. The Phase IIb result is now cited to its 2005 conference record and a 2026 peer-reviewed review.
CorrectionSemax
The 110-patient stroke finding is now cited to the correct study (Gusev et al., 2018). It was previously linked to a different 1997 study.
CorrectionThymosin Alpha-1
The TESTS sepsis trial is now cited to its primary paper (BMJ 2025).
Evidence updateSermorelin
Removed an unsourced reason for the withdrawal of Geref. The FDA record says only that it was not withdrawn for safety or effectiveness reasons.
CorrectionBPC-157
Removed an unsourced statement about how BPC-157 is sold in the UK. The same unsourced statement was removed from ten other profiles.
CorrectionBPC-157
UK status now cites a dated MHRA database check. Sport status confirmed from WADA's own 2026 Prohibited List (S0).
Regulatory updateTB-500
Sport status confirmed from WADA's own 2026 Prohibited List (S2.3, thymosin beta-4 and its derivatives).
Regulatory updateKisspeptin
UK status confirmed by a dated MHRA database check (no kisspeptin product found). WADA 2026 listing added.
Regulatory updateAOD-9604
UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.3).
Regulatory updateCJC-1295
UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).
Regulatory updateIpamorelin
UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).
Regulatory updateSermorelin
WADA 2026 listing added (S2.2.4).
Regulatory updateTesamorelin
WADA 2026 listing added (S2.2.4).
Regulatory updateSemax
UK status now cites a dated MHRA database check.
Regulatory updateSelank
UK status now cites a dated MHRA database check.
Regulatory updateEpithalon
UK status now cites a dated MHRA database check.
Regulatory updateTB-500
Removed a venous-ulcer trial finding: it tested full-length thymosin beta-4, not TB-500, and cited a trial-design paper rather than the results. Some figures in it were not in the published results. The Phase 1 safety finding now cites the original study. The scoping-review finding now says plainly that direct TB-500 evidence is a single study.
CorrectionTeriparatide
Teriparatide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileAbaloparatide
Abaloparatide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileSetmelanotide
Setmelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileAfamelanotide
Afamelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileElamipretide
Elamipretide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileMOTS-c
MOTS-c added: 4 findings and 0 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileKPV
KPV added: 5 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileGHRP-2
GHRP-2 added: 6 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileGHRP-6
GHRP-6 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileHexarelin
Hexarelin added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileThymosin beta-4
Thymosin beta-4 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.
New profileOxytocin
UK status re-checked against the official product information. All licensed obstetric uses are now listed.
Regulatory update
Subscribe to this log as a feed: changes.xml. No sign-up, nothing collected.
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.